Literature DB >> 8738727

A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions.

H Yano1, A Iemura, M Haramaki, S Momosaki, S Ogasawara, K Higaki, M Kojiro.   

Abstract

BACKGROUND/AIMS: Combined hepatocellular and cholangiocarcinoma is a rare tumor of the liver, and its histogenesis remains unclear. The authors addressed this issue in the current article.
METHODS: A specimen aseptically obtained from the surgically resected combined hepatocellular and cholangiocarcinoma was processed for primary culture. The morphologic features of the established cell line cultured on a plastic dish and in type I collagen gel matrix, and transplanted in nude mice were examined.
RESULTS: The authors established a new human combined hepatocellular and cholangiocarcinoma cell line, designated KMCH-2, from a 40-year-old Japanese man. KMCH-2 cells on a plastic dish proliferated in a monolayered sheet with a population doubling time of 32 to 44 h. KMCH-2 expressed functional characteristics of hepatocellular carcinoma, such as albumin synthesis at protein and mRNA levels, but were poorly differentiated in morphology, showing an overlap of features with cholangiocarcinoma. KMCH-2 cells cultured within type I collagen gel matrix proliferated, forming compact to vaguely trabecular and pseudoglandular arrangements, and differentiated to show morphological characteristics of hepatocellular carcinoma unlike the cells on a plastic dish. Mucin production was not detected in KMCH-2 cells in vitro. Subcutaneous tumors which developed in nude mice injected with KMCH-2 cells represented features of adenocarcinoma with mucin production.
CONCLUSIONS: The present results revealed the presence of an albumin-producing human hepatic neoplastic cell, such as KMCH-2, that can differentiate to show not only the features of hepatocellular carcinoma but also those of cholangiocarcinoma under certain growth conditions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738727     DOI: 10.1016/s0168-8278(96)80161-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  Combined hepatocellular cholangiocarcinoma: a case report and review of literature.

Authors:  Shailender Singh; Subhankar Chakraborty; Neelima Bonthu; Stanley Radio; Shahid M Hussain; Aaron Sasson
Journal:  Dig Dis Sci       Date:  2013-02-09       Impact factor: 3.199

2.  High level of CA19-9, CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo.

Authors:  M Watanabe; M Chigusa; H Takahashi; J Nakamura; H Tanaka; T Ohno
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-02       Impact factor: 2.416

Review 3.  Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines.

Authors:  Abdulkadir Isidan; Ali Yenigun; Daiki Soma; Eric Aksu; Kevin Lopez; Yujin Park; Arthur Cross-Najafi; Ping Li; Debjyoti Kundu; Michael G House; Sanjukta Chakraborty; Shannon Glaser; Lindsey Kennedy; Heather Francis; Wenjun Zhang; Gianfranco Alpini; Burcin Ekser
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

4.  Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study.

Authors:  Qian Zhao; Wen-Long Yu; Xin-Yuan Lu; Hui Dong; Yi-Jin Gu; Xia Sheng; Wen-Ming Cong; Meng-Chao Wu
Journal:  Chin J Cancer       Date:  2016-08-24

5.  Effect of sorafenib on des-γ-carboxyprothrombin secretion by a human hepatocellular carcinoma cell line.

Authors:  Sachiko Ogasawara; Masamichi Nakayama; Jun Akiba; Hironori Kusano; Hirohisa Yano
Journal:  Oncol Lett       Date:  2017-06-21       Impact factor: 2.967

Review 6.  Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer Type.

Authors:  Meng-Shin Shiao; Khajeelak Chiablaem; Varodom Charoensawan; Nuttapong Ngamphaiboon; Natini Jinawath
Journal:  Front Genet       Date:  2018-08-15       Impact factor: 4.599

7.  Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo.

Authors:  Hironori Kusano; Jun Akiba; Sachiko Ogasawara; Sakiko Sanada; Makiko Yasumoto; Masamichi Nakayama; Keiko Ueda; Kosuke Ueda; Takashi Kurita; Keita Todoroki; Yumi Umeno; Osamu Nakashima; Hirohisa Yano
Journal:  PLoS One       Date:  2013-12-12       Impact factor: 3.240

Review 8.  Treatment of Combined Hepatocellular and Cholangiocarcinoma.

Authors:  Simona Leoni; Vito Sansone; Stefania De Lorenzo; Luca Ielasi; Francesco Tovoli; Matteo Renzulli; Rita Golfieri; Daniele Spinelli; Fabio Piscaglia
Journal:  Cancers (Basel)       Date:  2020-03-26       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.